THE INTERNATIONAL GLIMER I, II & III MS STUDY
(Ongoing 2010 - 2025 Fifteen Year GLIMER Project - Extended 2019)

Jeremy David Block
BSc. (Eng.), MSc.(WCU), (Micro/Stats), D.Pharm (Wits)., PHD (Neuro IAGIM U)
Part Seven - 2019/7 - Total Parts 20 - Pages 110)

ALTERNATIVE MORE ADVANCED MS Article - www.LocumUSA.com ; Ref: "Article of the Month"
Prof. J. D. Block - Neuro-Immuno-Epidemiologist (N.I.E.)

Background: Prof. J D Block served for the duration of the development of COP 1 as a senior medical/pharmaceutical researcher and part of the Teva COP 1 innovative research team in the early nineties that rapidly developed Teva's first MS immuno-modulating drug Glatiramer Acetate (CopaxoneTM). As Chief Scientist as well as Teva Group Scientific Research Auditor, and by touching each and every part of Teva's overall scientific team Teva rapidly attained ND registration with the FDA under J. D. Block scientific and technical guidence and regulatory department training and overview.